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In January 1996, ECOG (Eastern Cooperative Oncology Group)
published the first prospective clinical trial (ECOG 1684) indi-
cating a significant increase in survival for patients with T4 or
N1 melanoma treated with adjuvant high-dose interferon alpha-2b
(IFN-a-2b; Kirkwood et al, 1996). Nevertheless, this treatment
was associated with moderate to severe side-effects for a long time
during and after treatment (Cole et al, 1996; Kirkwood et al,
1996). Therefore, apart from the issue of the indication for such a
treatment, and while waiting for the results of the forthcoming trial
ECOG 1690, we planned to treat patients with T4 or N1 melanoma
who were referred to our institutions with the identical ECOG
1684 treatment, and to evaluate prospectively the tolerance and
feasibility of this treatment outside a clinical trial.
MATERIALS AND METHODS
To be included, patients had to fulfill limited inclusion criteria.
Only patients with a cutaneous melanoma classified as T4 or N1
were treated. In the latter group, an extensive regional
lymphadenectomy was strongly recommended. The evaluation of
other underlying co-morbidity was left to the discretion of the
physician.
The planned treatment was a dose of 20 MIU m–2 IFN-a-2b
given intravenously, 5 days a week for 4 weeks (induction phase)
followed by subcutaneous IFN-a-2b at 10 MIU m–2, 3 times a
week for 11 months (consolidation phase) (Kirkwood et al, 1996).
The treatment had to start less than 6 weeks after the definitive
surgical treatment.
Toxicity was evaluated using the World Health Organization
(WHO) grading criteria. All patients received paracetamol and
anti-emetics for the first few days to prevent fever and nausea or
vomiting. Thereafter, symptomatic treatment was tailored to toxi-
city. Haematological and hepatic parameters were checked 1–3
times a week during the induction phase and 1–4 times a month
during the consolidation phase. Patients were seen by the physi-
cians weekly in the induction phase and monthly during the
consolidation phase. No mandatory dose modification was
planned but particular care was recommended for severe psychi-
atric disorders, grade 3 increase in transaminases and grade 4
neutropenia. Thyroid function was checked every 3–6 months
during treatment.
RESULTS
Thirty-six patients started treatment between March 1996 to
December 1997. Thirty-four patients had a N1 disease, of these, 31
had an extensive regional nodal dissection, one patient had a T4
disease and another had been treated for a single metastatic lesion
by surgery. The median age was 54, with a range from 8 to 75
years old.
Induction phase
During the induction phase, 17 patients received 100% and 24
(66.6%) more than 80% of the planned dose (Table 1). Thirteen
patients (36.1%) experienced grade 3 toxicity while five patients
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Summary To assess the feasibility and toxicity profile of high-dose interferon alpha-2b (IFN-a-2b) in the adjuvant treatment of patients with
cutaneous malignant melanoma outside the reference ECOG 1684 clinical trial, we conducted a prospective follow-up in an identical
population of patients (cutaneous melanoma, T4 and/or N1) treated by intravenous IFN-a-2b:20 MIU m–2, 5 days a week for 4 weeks; and
subcutaneous:10 MIU m–2, 3 times a week for 11 months. Thirty-six consecutive patients were considered in four different institutions. The
frequency and severity of side-effects related to IFN-a, as well as the percentage of the planned dose given to patients, were identical to
those reported in the initial report by ECOG. Fifty per cent and 47% of patients had a grade 3/4 WHO toxicity in the induction and
consolidation phase respectively. A dose modification was necessary for 47.2% and 55.8% of the patients in the induction and consolidation
phase respectively. The schedule and dose of high-dose IFN-a-2b in the adjuvant treatment of cutaneous malignant melanoma, as reported
by ECOG 1684, is feasible. The significant toxicity reported in ECOG 1684 was also seen in our patients. Nevertheless, this protocol will not
be a ‘standard’ treatment until the publication of the ECOG 1690 trial.
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Correspondence to: A Ravaud(13.9%) experienced grade 4 toxicity. The main clinical toxicities
were asthenia, fever, nausea, vomiting and psychiatric disorders
(Table 2). All except six patients developed neutropenia, with
grade 3 or 4 toxicity in 12 patients. Five patients had grade 3
hepatic cytotoxicity. Seventeen patients (47.2%) required either
discontinuation or dose reduction because of toxicity.
Consolidation phase
For the purpose of analysis, the maintenance phase was divided
into four time periods: 1–3 months, 4–6 months, 7–9 months and
10–11 months (Tables 3 and 4). All patients were considered for
toxicity.
The reasons for discontinuation of treatment were disease
progression (14 patients) and toxicity (five patients) (Table 3).
Another patient had a pregnancy after 9 months of treatment.
From months 1–3 of the consolidation treatment, 23/34 patients
received 100% of the planned dose of IFN-a, while 17/31, 13/26
and 7/17 patients did so in the subsequent consolidation phases
respectively (Table 1).
Seven patients had at least a grade 4 toxic event and nine at least
grade 3 side-effects related to treatment during the overall consol-
idation phase. The most frequent severe clinical side-effects were
asthenia and psychiatric disorders, while neutropenia and an
increase in transaminases were the most frequent severe treatment-
related biological changes (Table 4). Any side-effects were
regularly reported irrespective of the period. Throughout the
consolidation treatment, 19/34 patients (55.8%) who started the
consolidation phase had either a dose reduction or discontinued
therapy due to toxicity.
End of treatment
Sixteen patients (44.4%) among the 36 initial patients completed
the treatment after 12 months of IFN-a-2b.
DISCUSSION
Owing to the results of the ECOG 1684 study (Kirkwood et al,
1996), IFN-a-2b is now licensed for use as adjuvant therapy in
patients with a high-risk melanoma. Although this treatment
cannot be considered as standard until the results are confirmed by
another trial (ECOG 1690), we felt it was useful to test whether
this treatment is feasible in terms of schedule, dose and toxicity
outside the reference trial.
In comparison to the initial study of the ECOG, our results do
not differ for the total given dose of IFN-a-2b, for toxicity or for
the incidence of disease progression during treatment.
Whereas in the ECOG 1684 study (Kirkwood et al, 1996),
72.7% of patients received more than 80% of the theoretical
dose, 66.6% did so in our study during the induction phase.
Nevertheless, this period needs a thorough clinical and biological
follow-up to check for the occurrence of grade 3 or 4 toxicity
which was encountered by 50% of our patients and at least in 37%
in the ECOG study (Kirkwood et al, 1996).
Significant toxicity was also seen in the consolidation phase, as
16 patients (47%) experienced a grade 3 or 4 toxicity, a similar
figure to that in the ECOG study.
CONCLUSION
Adjuvant treatment with high-dose IFN-a-2b for patients with
malignant cutaneous melanoma, as reported by ECOG (Kirkwood
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Table 1 Dose of IFN-a-2b
Number of patients receiving 100% > 80% (%)
Induction phase 17/36 24/36 (66.6)
Consolidation phase
1–3 months 23/34 24/34 (70.6)
4–6 months 17/31 21/31 (67.8)
7–9 months 13/26 13/26 (50)
10–11 months 7/17 10/17 (58.8)
Table 2 Toxicity by type and degree during induction phase
WHO grade (n = 36) 1 2 3 4
Asthenia 11 9 5 1
Fever 2 13 1 –
Nausea/vomiting 12 2 3 –
Diarrhoea 2 – 1 –
Psychiatric disorders 4 4 1 1
Headache/myalgia – 4 1 –
Alopecia 4 – – –
Infectious process – 1 1 1
Neutropenia 7 10 9 3
Thrombopenia 2 – – –
Hepatic transaminitis 4 8 5 –
Others 1 2 – –
Total number of events 49 53 27 6
Table 3 Feasibility of treatment
Phase Induction Consolidation
1 month
1–3 months 4–6 months 7–9 months 10–11 months
Number of patients at start in a given period 36 34 31 26 17 16
Stop treatment due to toxicity 1 2 0 2 0
Stop due to disease progression 1 1 5 6 1
Pregnancy 1et al, 1996), is feasible. Our results do not differ from those of the
reference study in terms of schedule and the dose given of IFN-a-
2b. Moreover, the significant toxicity reported by Kirkwood was
also seen in our study.
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Table 4 Toxicity by type and degree during the different periods of consolidation phase (WHO grade)
Period 1 2 3 4 Number of patients
for period
Asthenia 1–3 14 8 4 1 34
4–6 12 9 4 2 31
7–9 12 4 1 2 26
10–11 9 3 2 – 17
Fever 1–3 5 1 – – 34
4–6 5 1 – – 31
7–9 2 1 – – 26
10–11 – 1 – – 17
Nausea/vomiting 1–3 11 2 – – 34
4–6 11 1 – – 31
7–9 6 – – – 26
10–11 7 – – – 17
Psychiatric disorders 1–3 2 5 1 1 34
4–6 2 5 3 – 31
7–9 1 7 – – 26
10–11 1 4 – 1 17
Headache/myalgia 1–3 1 2 – – 34
4–6 – 2 – – 31
7–9 – 2 – – 26
10–11 – 1 – – 17
Alopecia 1–3 5 2 1 – 34
4–6 8 1 1 – 31
7–9 5 3 – – 26
10–11 4 2 – – 17
Neutropenia 1–3 10 9 3 1 34
4–6 5 15 5 1 31
7–9 6 11 3 1 26
10–11 4 5 4 – 17
Hepatic transaminitis 1–3 6 – 3 – 34
4–6 6 2 – – 31
7–9 4 1 – – 26
10–11 1 2 – – 17